BTG Btg Plc

TIDMBTG

RNS Number : 2225R

BTG PLC

20 September 2017

BTG plc: legal ruling

London, UK, 20 September 2017: BTG plc (LSE: BTG), the global specialist healthcare company, announces that a Memorandum Opinion has been issued by the Court of Chancery of Delaware ruling against BTG in its previously announced litigation with Wellstat Therapeutics Corporation concerning the commercialisation of Vistogard(R) . The Court has found that BTG has breached the distribution agreement and that Wellstat is entitled to damages of $55.8m plus interest and costs.

BTG is surprised and disappointed by the Opinion and is considering options, which include appealing the ruling and level of damages awarded.

For further information contact

BTG

Andy Burrows, VP Corporate & Investor Relations

+44 (0)20 7575 1741; Mobile: +44 (0)7990 530 605

Stuart Hunt, Investor Relations Manager

+44 (0)20 7575 1582; Mobile: +44 (0)7815 778 536

Chris Sampson, Corporate Communications Director

+44 (0)20 7575 1595; Mobile: +44 (0)7773 251 178

FTI Consulting

Ben Atwell/Simon Conway

+44 (0)20 3727 1000

About BTG

BTG is a global specialist healthcare company bringing to market innovative products in specialist areas of medicine to better serve doctors and their patients. We have a portfolio of Interventional Medicine products to advance the treatment of cancer, severe emphysema, severe blood clots and varicose veins, and Specialty Pharmaceuticals that help patients overexposed to certain medications or toxins. Inspired by patient and physician needs, BTG is investing to expand its portfolio to address some of today's most complex healthcare challenges. To learn more about BTG, please visit: btgplc.com.

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCEAENNFDFXEAF

(END) Dow Jones Newswires

September 20, 2017 02:00 ET (06:00 GMT)

Btg (LSE:BTG)
Historical Stock Chart
From Apr 2024 to May 2024

Btg (LSE:BTG)
Historical Stock Chart
From May 2023 to May 2024